Lives unaffected by cystic fibrosis


Back to the Drug Development Pipeline


Phase Two

Phase Two

Therapeutic Approach


This program is studying BX004-A, a type of phage therapy intended to treat Pseudomonas aeruginosa infections in the lung. Bacteriophages are specialized viruses that kill very specific bacterial strains. They are found in the environment and are the predators of bacteria in nature. “Phage therapy” refers to the use of these bacteriophages to treat an infection in a person.

In lab studies, BX004-A was shown to be active against antibiotic-resistant strains of P. aeruginosa and demonstrated the ability to penetrate biofilm, a naturally forming structure that makes bacteria more resistant to antibiotics.


A phase 1b/2a study of BX004-A in adults with CF who have chronic Pseudomonas aeruginosa infections is planned.


This program is sponsored by BiomX and is partially funded by the Cystic Fibrosis Foundation. Clinical trials will be conducted through the Therapeutics Development Network.

Contact us about BX004-A >